Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: A EUSTAR group-based study

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.76, 2013, Pages

  Heijnen, Ingmar A F M ^a   Foocharoen, Ching ^b   Bannert, Bettina ^c   Carreira, Patricia E ^d   Caporali, Roberto ^e   Smith, Vanessa ^f   Kumánovics, Gábor ^g   Becker, Mike O ^h   Vanthuyne, Marie ⁱ   Simsek, Ismail ^j   Bocelli Tyndall, Chiara ^c   Walker, Ulrich A ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b KHON KAEN UNIVERSITY   (Thailand)

^c Felix Platter Spital   (Switzerland)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e UNIVERSITY OF PAVIA   (Italy)

^f GHENT UNIVERSITY   (Belgium)

^g UNIVERSITY OF PÉCS   (Hungary)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^j GULHANE SCHOOL OF MEDICINE   (Turkey)

more..

Author keywords

Anticentromere antibodies; Antitopoisomerase I antibodies; Systemic sclerosis

Indexed keywords

CENTROMERE ANTIBODY; DNA TOPOISOMERASE; DNA TOPOISOMERASE ANTIBODY; ENZYME ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COR PULMONALE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LUNG DISEASE; LUNG FIBROSIS; MALE; MUSCULOSKELETAL DISEASE; PREVALENCE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REPEAT PROCEDURE; SKIN DISEASE; SKIN MANIFESTATION; SYSTEMIC SCLEROSIS; BLOOD; CENTROMERE; COHORT ANALYSIS; DIFFUSE SCLERODERMA; EPIDEMIOLOGY; FACTUAL DATABASE; IMMUNOLOGY; LIMITED SCLERODERMA; MIDDLE AGED;

ADULT; AGED; AUTOANTIBODIES; CENTROMERE; COHORT STUDIES; DATABASES, FACTUAL; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC; SEROEPIDEMIOLOGIC STUDIES;

EID: 84883765615     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. DENTON CP, BLACK CM, ABRAHAM DJ: Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006; 2: 134-44.
2. WALKER JG, FRITZLER MJ: Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007; 19: 580-91.
3. HO KT, REVEILLE JD: The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003; 5: 80-93.
4. IOANNIDIS JP, VLACHOYIANNOPOULOS PG, HAIDICH AB et al.: Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118: 2-10.
5. KOENIG M, JOYAL F, FRITZLER MJ et al.: Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58: 3902-12.
6. SPENCER-GREEN G, ALTER D, WELCH HG: Test performance in systemic sclerosis: anticentromere and anti-Scl-70 antibodies. Am J Med 1997; 103: 242-8.
7. REVEILLE JD, SOLOMON DH: Evidencebased guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003; 49: 399- 412.
8. KOENIG M, DIEUDE M, SENECAL JL: Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008; 7: 588- 93.
9. BIZZARO N, TONUTTI E, VILLALTA D et al.: Sensitivity and specificity of immunological methods for the detection of anti-topoisomerase I (Scl70) autoantibodies: results of a multicenter study. The Italian Society of Laboratory Medicine Study Group on the Diagnosis of Autoimmune diseases. Clin Chem 2000; 46: 1681-5.
10. VOLPE A, RUZZENENTE O, CARAMASCHI P et al.: Clinical associations of anti-CENP-B and anti-Scl70 antibody levels measured by multiplexed fluorescent microsphere immunoassay in systemic sclerosis. Rheumatol Int 2009; 29: 1073-9.
11. WALKER UA, TYNDALL A, CZIRJAK L et al.: Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754-63.
12. Subcommittee for scleroderma criteria of the American Rheumatism Ass ociation Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
13. KIKUCHI M, INAGAKI T: Bibliographical study of the concurrent existence of anticen tromere and antitopoisomerase I antibodies. Clin Rheumatol 2000; 19: 435-41.
14. DICK T, MIERAU R, BARTZ-BAZZANELLA P et al.: Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis. Ann Rheum Dis 2002; 61: 121-7.
15. SCUSSEL-LONZETTI L, JOYAL F, RAYNAULD JP et al.: Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81: 154-67.
16. JARZABEK-CHORZELSKA M, BLASZCZYK M, KOLACINSKA-STRASZ Z et al.: Are ACA and Scl 70 antibodies mutually exclusive? Br J Dermatol 1990; 122: 201-8.
17. DOUVAS AS, ACHTEN M, TAN EM: Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979;254:10514-22.
18. MOROI Y, PEEBLES C, FRITZLER MJ et al.: Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 1980; 77: 1627-31.
19. VAZQUEZ-ABAD D, RUSSELL CA, CUSICK SM et al.: Longitudinal study of anticentromere and antitopoisomerase-I isotypes. Clin Immunol Immunopathol 1995; 74: 257-70.
20. KUWANA M, KABURAKI J, MIMORI T et al.: Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000; 43: 1074-84.
21. MURATORI P, MURATORI L, CASSANI F et al.: Anti-multiple nuclear dots (anti- MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol 2002; 127: 172-5.
22. SPENCER-GREEN G, ALTER D, WELCH HG: Test performance in systemic sclerosis: anticentromere and anti-Scl-70 antibodies. Am J Med 1997; 103: 242-8.
23. BOSSUYT X: Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev 2009; 8: 543-8.
24. FUJIMOTO M, SHIMOZUMA M, YAZAWA N et al.: Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/SS-A autoantibodies in Japanese patients with systemic sclerosis. Ann Rheum Dis 1997; 56: 667-70.
25. PARKER JC, BURLINGAME RW, BUNN CC: Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis. J Autoimmune Dis 2009; 6: 2.
26. WALKER UA, TYNDALL A, CZIRJAK L et al.: Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis 2009; 68: 856-62.
27. KUWANA M, KABURAKI J, MIMORI T et al.: Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000; 43: 1074-84.
28. SATO S, HAMAGUCHI Y, HASEGAWA M et al.: Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology 2001; 40: 1135-40.
29. McSWEENEY PA, NASH RA, SULLIVAN KM et al.: High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002; 100: 1602-10.
30. BARNETT AJ, McNEILAGE LJ: Antinuclear antibodies in patients with scleroderma (systemic sclerosis) and in their blood relatives and spouses. Ann Rheum Dis 1993; 52: 365-8.
31. SIMEON CP, FONOLLOSA V, TOLOSA C et al.: Association of HLA class II genes with systemic sclerosis in Spanish patients. J Rheumatol 2009; 36: 2733-6.
32. ARNETT FC, GOURH P, SHETE S et al.: Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African- American and Hispanic cases and 1000 controls. Ann Rheum Dis 2010; 69: 822-7.
33. GORLOVA O, MARTIN JE, RUEDA B et al.: Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet 2011; 7: e1002178.
34. LeROY EC, MEDSGER TA, Jr.: Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.